Sol-Gel Technologies

Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.

NESS ZIONA, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in H.C. Wainwright's 23rd Global Investment Conference.

Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference

NESS ZIONA, Israel, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial results for the second quarter ended June 30, 2021 and provided an overview of recent corporate developments.

Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

SolGel Technologies Ltd. (SLGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

SolGel Technologies Ltd. (SLGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

The FDA has approved Sol-Gel Technologies Ltd's (NASDAQ: SLGL) first proprietary drug product, Twyneo (tretinoin/benzoyl peroxide) cream, 0.1%/3%, indicated for acne vulgaris in adults and pediatric patients nine years of age and older. Twyneo uses Sol-Gel's patented technology to entrap tretinoin, a retinoid, and benzoyl peroxide within silica-based microcapsules to stabilize tretinoin from being degraded by benzoyl peroxide and to release each of the active drug ingredients slowly.

Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris

NESS ZIONA, Israel, July 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Food and Drug Administration (FDA) has approved its first proprietary drug product, TWYNEO (tretinoin/benzoyl peroxide) cream, 0.1%/3%, indicated for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older. TWYNEO uses Sol-Gel's patented technology to entrap tretinoin, a retinoid, and benzoyl peroxide within silica-based microcapsules to stabilize tretinoin from being degraded by benzoyl peroxide and to slowly release each of the active drug ingredients over time to provide a favorable efficacy and safety profile. TWYNEO is patent protected until 2038. Sol-Gel has partnered with Galderma to commercialize TWYNEO in the U.S. Sol-Gel expects to receive a regulatory milestone payment in conjunction with this approval and retains the option to regain U.S. commercialization rights five years following first commercialization in the U.S.

Sol-Gel Technologies Announces FDA Approval of TWYNEO®

NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET.

Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

NESS ZIONA, Israel, June 28, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced positive pre-clinical data for SGT-510, its investigational topical roflumilast drug candidate and provided a corporate update.

Sol-Gel Announces Pipeline Update and Future Development Plans

NESS ZIONA, Israel & LAUSANNE, Switzerland--(BUSINESS WIRE)--Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world's largest independent dermatology company, today announced they have signed two exclusive 5-year license agreements for the commercialization of EPSOLAY® and TWYNEO® in the United States. Under these agreements, Galderma has an exclusive license to commercialize Sol-Gel's most advanced investigational drug products using Sol-Gel's

Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States

- Sol-Gel is in advanced negotiations with a potential partner regarding the commercialization of EPSOLAY ® and TWYNEO ®

Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update

NEW YORK, April 28, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sol-Gel Technologies Ltd. ("Sol-Gel" or the "Company") (NASDAQ: SLGL) Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sol-Gel Technologies Ltd. - SLGL

Bionano Genomics

DermTech Inc

Aldeyra Therapeutics

Cyclerion Therapeutics Inc

Cyclerion Therapeutics, Inc. (NASDAQ: CYCN), Sol-Gel Technologies Ltd. (NASDAQ: SLGL), Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), DermTech, Inc. (NASDAQ: DMTK) and Bionano Genomics, Inc. (NASDAQ: BNGO) are among the biggest health care movers Tuesday.

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

NESS ZIONA, Israel, April 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced an update regarding the U.S. Food and Drug Administration (FDA) approval process for EPSOLAY® (benzoyl peroxide) 5% topical cream for the treatment of Inflammatory lesions of rosacea in adults.

Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®

SolGel Technologies Ltd. (SLGL) was a big mover last session on higher-than-average trading volume.

SolGel Technologies Ltd. (SLGL) Moves 9.7% Higher: Will This Strength Last?

SolGel Technologies Ltd. (SLGL) witnessed a jump in share price last session on above-average trading volume.

SolGel Technologies Ltd. (SLGL) Stock Jumps 10.8%: Will It Continue to Soar?

SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 12.20% and -725.03%, respectively, for the quarter ended December 2020.

SolGel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates

• Epsolay ® and Twyneo ® PDUFA goal date s set for April 26 , 2021 and August 1 , 2021 respectively

Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update

NESS ZIONA, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present an overview of the Company and provide a business update at the following virtual investor conferences.

Sol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global Life Sciences Conference

NESS ZIONA, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present an overview of the Company and provide a business update at the following virtual investor conferences.

Sol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Conference

Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo® for the Treatment of Acne Vulgaris

Sol-Gel Technologies (SLGL) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Sol-Gel Technologies (SLGL) Looks Good: Stock Adds 8.8% in Session

Patented technology for slow release of topical formulations. Potentially the first single-active benzoyl peroxide to be approved as a prescription drug.

Sol-Gel: Slow And Steady Topical Technology

Shares of Sol-Gel Technologies (NASDAQ:SLGL) moved higher by 0.1% after the company reported Q3 results. Quarterly Results Earnings per share increased 0.00% year over year to ($0.37), which beat the estimate of ($0.46).

Recap: Sol-Gel Technologies Q3 Earnings

NESS ZIONA, Israel, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial results for the third quarter ended September 30, 2020 and provided clinical and regulatory updates on its programs.

Sol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update

NESS ZIONA, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present at the following upcoming virtual investor conferences.

News for Sol-Gel Technologies Stock (SLGL)